Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navarixin - Ligand Pharmaceuticals/Merck & Co.

Drug Profile

Navarixin - Ligand Pharmaceuticals/Merck & Co.

Alternative Names: MK-7123; PS-291822; SCH 527123; SCH 5271234

Latest Information Update: 03 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmacopeia; Schering-Plough
  • Developer Ligand Pharmaceuticals; Merck & Co
  • Class Anti-inflammatories; Benzamides; Cyclobutanes
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Asthma; Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Apr 2018 Phase-II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Israel (PO) (NCT03473925)
  • 22 Mar 2018 Merck & Co. plans a phase II trial of navarixin in combination with pembrolizumab for Solid tumours (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) (NCT03473925)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top